Name | ALK5 |
---|---|
Synonyms | AAT 5; AAT5; ACVRLK 4; ACVRLK4; ALK 5; ALK5; Activin A receptor type II like kinase 53kD; Activin receptor like kinase 5… |
Name | SMA |
---|---|
CAS | sodium 2-chloroacetate |
PubMed | Abstract | RScore(About this table) | |
---|---|---|---|
17990457 | Liu YM, Zhang Y, He LQ: [Experimental study on effect of Kangxianling on rat renal interstitial fibrosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Oct;27(10):901-4. Then rats were sacrificed, their renal pathology examined by HE staining and PASM staining; expressions of transforming growth factor-beta1 (TGF-beta1), hepatocyte growth factor (HGF) mRNA, and a-smooth muscle actin (alpha-SMA), TGF-beta1 receptor I (TbetaR I), TGF-beta1 receptor II (TbetaR II) and hepatocyte growth factor receptor (C-Met) protein in kidney tissue were determined by RT-PCR and Western blotting respectively. |
4(0,0,0,4) | Details |
19375841 | Yoo YA, Kang MH, Kim BS, Kim JS, Seo JH: Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation. Differentiation. 2009 Jun;77(5):450-61. Epub 2009 Apr 17. |
4(0,0,0,4) | Details |
20015471 | Wang QL, Yuan JL, Tao YY, Zhang Y, Liu P, Liu CH: Fuzheng Huayu recipe and renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition. J Ethnopharmacol. 2010 Feb 17;127(3):631-40. Epub 2009 Dec 16. HK-2 cells were treated with TGF-beta1 for 24h, followed by incubation with either SB-431542 (a potent and specific inhibitor of TbetaR-I kinase) or FZHY drug-containing serum for another 24h. |
reverse 4(0,0,0,4) | Details |
19193641 | Webber J, Meran S, Steadman R, Phillips A: This persistence was because of autocrine synthesis of TGF-beta1, which was inhibited by both anti-TGF-beta1 antibody and the ALK5 inhibitor SB431542. |
orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem. 2009 Apr 3;284(14):9083-92. Epub 2009 Feb 4.1(0,0,0,1) | Details |